All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The EU-28 average of female labor market participation for women aged 25 to 54 rose from 67% in 2001 to 72% in 2014. In Spain, the percentage of employed women in this age range increased from 53% to 62% during the same period \[[@pone.0237794.ref001]\]. This increase in female employment has lead to the recognition of the double burden working women often encounter as they navigate the demands of paid employment and unpaid domestic work, which may partly explain why women have higher sickness absence (SA) than men \[[@pone.0237794.ref002]\].

Similarly, the demands of pregnancy have been posited as another cause of higher SA in women \[[@pone.0237794.ref002]\]. The medical consensus is that maternity is a biological process, although health in pregnancy faces high physiological and psychological demands, which could lead to health problems \[[@pone.0237794.ref003]\], either work-related or not. In fact, a precipitous increase in the amount of sickness absence benefits used can be seen during pregnancy \[[@pone.0237794.ref004]\]. This situation may contribute to pregnancy workplace discrimination, in which pregnant women are subject to perceptions including being less committed to their job and creating more work for colleagues \[[@pone.0237794.ref005]\]. Even pregnancies without exposure to occupational risk factors may face symptoms such as nausea and vomiting, headaches, back pain, and fatigue \[[@pone.0237794.ref006]\], though even these diseases have been shown to decrease health-related quality of life in pregnant women \[[@pone.0237794.ref007]\]. Evidence demonstrates the relation between occupational exposures and health effects during pregnancy, such as an increase in the number of low birth weight and prematurity in relation to a heavy physical workload \[[@pone.0237794.ref008]\]. To deal with this situation, and protect both the health of working women and the fetus, as well as support continuity in their employment, many countries, including Spain, have developed specific social protection benefits. The most relevant social protection benefit for workers, men and women, with a health problem are sickness absence benefits. The International Labour Organization defines SA as a situation in which a worker is unable to perform the essential tasks demanded by his or her workplace as a consequence of a diversion from their habitual state of health, and it can be considered as a social right that allows the worker to be temporarily absent from the workplace due to non-permanent health-related causes while he or she receives medical care \[[@pone.0237794.ref009]\].

The sickness absence benefit in Spain is a social benefit from which any worker can benefit given that they have been affiliated to the Social Security System. For common disease, not occupational injury or disease, current legislation requires that the sick leave be certified by a National Health System physician in order to offer a diagnosis and recognize the absence from work as SA. SA spells are recorded for all health-related absences recognized by a National Health System physician beginning on the day the physician certifies the absence until the health condition initiating the absence is resolved, or in extreme instances, when the condition cannot be resolved and permanent disability is required. After the third day of absence, the employee's wages are covered between 60% and 70%, first by the employer, until the sixteenth day of absence when the National Social Security Institute begins to pay until the end of the SA episode \[[@pone.0237794.ref010]\]. Due to the differences in sickness absence benefits between countries, it is not clear whether research findings from other countries are applicable to the Spanish worker.

Compared to younger workers, a greater risk of SA in older individuals has been described \[[@pone.0237794.ref011]\], as well as a higher incidence in women in comparison to men, but the cause of the gender difference is poorly studied \[[@pone.0237794.ref012],[@pone.0237794.ref013]\]. A study in Sweden found that female workers have higher incidence of SA during pregnancy compared to the years prior and posterior to their pregnancy \[[@pone.0237794.ref004]\]. Although sickness absence benefits are not designed as a family policy benefit, female workers may use it as a tool to care for their health and that of their fetus when adverse work exposures are not adequately mitigated in advance, or when family policy benefits are deficient.

In Spain, maternity leave benefits provide women 16 continuous weeks of leave paid at 100% of their normal salary. Six of these weeks must be used directly after birth, but the remaining 10 weeks may be used before or after the birth, donated to the woman's partner, or any combination thereof \[[@pone.0237794.ref014]\]. In 2014, of those who provided a response, 53% of women who gave birth in Catalonia described themselves as being active in the labor market \[[@pone.0237794.ref015]\]. In that same year, the total fertility in Spain was 1.32 \[[@pone.0237794.ref016]\], and a 2015 estimate suggests that the median age of the mother at first birth was 30.7 years for Spain \[[@pone.0237794.ref017]\]. Overall, Spain is characterized as having lower fertility and an older age at first birth than the rest of the EU \[[@pone.0237794.ref016],[@pone.0237794.ref017]\].

Various Norwegian studies demonstrated that the incidence of SA during pregnancy is rising, though the cause is not apparent \[[@pone.0237794.ref018]\]. In fact, a study examining SA in Spain reported that obstetric diagnoses accounted for 14% of all SA episodes lasting at least 15 days in working persons without differentiating between men and women \[[@pone.0237794.ref019]\]. Further exploration of the behavior of SA according to reproductive age is compelling given the poorly explained gender gap in SA. Moreover, a broad description of SA across age and disease states is, at the time of this publication, insufficient to understand the potential causes of this gender gap in a Southern European state such as Spain, which has a weaker welfare state than Northern European countries, where this phenomenon is better described. The aim of this study is to compare the incidence rates of overall SA and according to specific diseases among early-, middle-, and late-reproductive age groups in female workers in Catalonia (Spain) between 2012 and 2014.

Methods {#sec006}
=======

Study population {#sec007}
----------------

The study population belongs to a cohort of 64,361 working women, affiliated to the Spanish Social Security as employees (general regime), which covers all workers with formal employment. The study period went from the beginning of 2012 to the end of 2014. The sample used in this study is drawn from the Spanish WORKss cohort \[[@pone.0237794.ref020]\]. The WORKss cohort is the result of merging two administrative registries: the Continuous Working Life Sample (MCVL) from the Social Security Institute, and the Catalonian Institute of Medical Evaluations (ICAMS) from the Department of Health ([Fig 1](#pone.0237794.g001){ref-type="fig"}). A detailed description of the WORKss Cohort has previously been described by López Goméz and colleagues \[[@pone.0237794.ref020]\].

![Construction of WORKss cohort and final study sample.](pone.0237794.g001){#pone.0237794.g001}

The MCVL, designed to help the Social Security Institute to manage contributions and payments \[[@pone.0237794.ref021]\], annually collects occupational information from a 4% representative sample of the Spanish population associated with the Social Security System, including SA data and employment characteristics \[[@pone.0237794.ref020]\]. The annual reference population for the MCVL is any individual who has contributed to or received payments from Social Security at any point during that year. Individuals are selected to the MCVL based on a simple random sample, and remain a part of the MCVL indefinitely until they contribute to or receive from the Social Security at any point over a full calendar year. New individuals enter the MCVL every year until the sample reaches 4% of the population \[[@pone.0237794.ref020]\]. While the MCVL is a robust sample that allows for the inclusion of individuals with infrequent employment, it excludes some categories of civil servants covered by distinct insurance funds, such as university professors and military personnel \[[@pone.0237794.ref022]\], which represent about 5% of the Spanish working population \[[@pone.0237794.ref020]\]. ICAMS records SA medical diagnoses for all resident workers in Catalonia. The record linkage between both registries was carried out following an agreement with the Social Security authority.

Variables {#sec008}
---------

The dependent variable was the total number of SA spells initiated between 2012--2014. An SA spell was defined as any absence from work due to common disease as certified by a physician, as is required by law. For the independent variable, women were assigned to one of three age categories based on their age as of December 31, 2012, and following birthrates from Catalonia during the study period: early-reproductive age (25--34), middle-reproductive age (35--44), and late-reproductive age (45--54). In Catalonia, between 2012 and 2014, more than 97% of the pregnancies corresponded to women with ages between 20 and 44. The birthrates in this population in the year 2014 demonstrated that women between 25 and 34 years had the highest birthrate (40.26 births/1000 persons), followed by women between 35 and 44 years (19.63 births/1000 persons). Women in the age group of 45--54 had the lowest birth rate (0.36 births/1000 persons) \[[@pone.0237794.ref015]\]. After excluding women under 25, because they had relatively low birth and employment rates (8.76 births/1000 persons and below 25%, respectively), and women over 54 (natality data not reported), 16,482 women were removed and the final sample size was 47,879 women, or about 4.2% of the female working population between 25 and 54 years of age in Catalonia \[[@pone.0237794.ref015]\].

SA medical diagnoses were coded according to the 10^th^ edition of the International Classification of Diseases (ICD-10). Occupational category (skilled non-manual, unskilled non-manual, skilled manual, unskilled manual); type of contract (permanent, temporary); and country of origin (Spain and other EU-28 states, and all other countries) were considered as potential confounders. Occupational category and type of contract were assigned based on the situation to which the woman was affiliated for the most time over the three-year period of this study.

Statistical analyses {#sec009}
--------------------

SA incidence rates (IR) were calculated for women of each reproductive age group, according to diagnostic group, type of contract, occupational category, country of origin, and specific diseases. The IR was calculated as the number of SA spells per 100 person-years at risk. Person-year at risk was defined as the sum of days affiliated to the Social Security system, subtracting days on SA, and dividing by 365.33 (accounting for leap year in 2012). Confidence intervals at 95% were estimated for each of the incidence rates calculated.

Within the diagnostic groups that showed significant differences among reproductive age groups, diseases that represented at least 5% of all diagnoses in the group, were also assessed. The perinatal diagnostic group was not considered in this analysis as these codes refer exclusively to neonates.

Incidence risk ratios (IRR) were calculated using crude and adjusted Poisson and negative binomial models, with the data presented deriving from whichever of the two demonstrated the higher log likelihood. Consequently, IRR values are based on Poisson models for overall SA, and negative binomial models were used for specific diseases in order to compare the incidence rates of SA among age groups. All analyses were performed using STATA Version 13.

Ethics {#sec010}
------

The protocol for the study described in this article (2018/8036/I), was approved by the Clinical Ethics Committee at *Parc de Salut Mar* in Barcelona, Spain. Written informed consent from those included in the cohort was not required. All data were anonymized and deidentified before the authors had access to them.

Results {#sec011}
=======

There were less women in the late-reproductive group than the early- or middle-reproductive groups. Across all age groups, women were most commonly characterized as having a permanent contract, working in an unskilled non-manual job, and originating from Spain or other EU country. The distribution of occupational and demographic characteristics were similar across all age groups ([Table 1](#pone.0237794.t001){ref-type="table"}).

10.1371/journal.pone.0237794.t001

###### Occupational and demographic characteristics in female workers by age group, Catalonia 2012--2014.

![](pone.0237794.t001){#pone.0237794.t001g}

                              Early-Reproductive   Middle-Reproductive   Late-Reproductive                   
  --------------------------- -------------------- --------------------- ------------------- ------ -------- ------
  **Contract**                                                                                               
      Permanent               11,153               64.2                  13,163              73.3   9,888    78.8
      Temporary               6,222                35.8                  4,795               26.7   2,657    21.2
  **Occupational Category**                                                                                  
      Skilled non-manual      3,740                21.5                  3,813               21.2   2,318    18.5
      Unskilled non-manual    8,271                47.6                  8,265               46.0   5,284    42.1
      Skilled manual          3,131                18.0                  3,127               17.4   2,312    18.4
      Unskilled manual        2,233                12.9                  2,754               15.3   2,631    21.0
  **Country of Origin**                                                                                      
      Spain and EU-28         13,155               78.1                  14,502              82.5   10,699   86.8
      Other                   3,668                21.9                  3,077               17.5   1,628    13.2
  **Overall**                 17,375               100                   17,959              100    12,545   100

The 47,879 women included in the sample accumulated a total of 38,242 SA episodes from 2012 to 2014. The overall incidence rate of SA was significantly higher in early-reproductive age women (43.62 spells/100 person-years), followed by middle-reproductive age women (35.03 spells/100 person-years), and this rate was the lowest in the late-reproductive group (32.65 spells/100 person-years). This descending trend was maintained at a statistically significant level across both contract types, women with skilled non-manual and unskilled manual occupations and women born in EU-28 countries. However, there were no significant differences in the incidence rates between age groups among immigrants from outside of the EU. Though the median duration of SA varies widely depending primarily on the diagnostic group, overall SA episodes are longer for women in the late reproductive group than for early- or middle-reproductive groups ([Table 2](#pone.0237794.t002){ref-type="table"}).

10.1371/journal.pone.0237794.t002

###### Incidence rates of sickness absence in female workers by age group, according to diagnostic group, contract, occupational category, and country of origin, Catalonia 2012--2014.
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                                           Early-Reproductive                    Middle-Reproductive                   Late-Reproductive                                                                                         
  ------------------------------- -------- -------------------- -------- ------- --------------------- ------ -------- ------------------- -------- ------- -------------- ------ ------- ------ -------- ------- -------------- ------
  **Diagnostic Group (ICD10)**                                                                                                                                                                                                   
      Infectious (A00-B99)        2,195    13.6                 35,784   6.25    5.99--6.51            2      1,611    11.1                40,022   4.09    3.89--4.29     3      838     8.5    28,419   3.00    2.80--3.20     3
      Neoplasms (C00-D49)         170      1.1                  35,784   0.48    0.41--0.55            15     371      2.6                 40,022   0.94    0.85--1.04     19     339     3.4    28,419   1.21    1.08--1.34     24.5
      Hematological (D50-D89)     36       0.2                  35,784   0.10    0.07--0.14            19     49       0.3                 40,022   0.12    0.09--0.16     16     25      0.3    28,419   0.09    0.05--0.12     20
      Metabolic (E00-E89)         65       0.4                  35,784   0.19    0.14--0.23            10     79       0.5                 40,022   0.20    0.16--0.24     19     57      0.6    28,419   0.20    0.15--0.26     25
      Mental (F01-F99)            1,062    6.6                  35,784   3.02    2.84--3.21            18     1,132    7.8                 40,022   2.87    2.71--3.04     17     851     8.6    28,419   3.04    2.84--3.25     22
      Nervous system (G00-G99)    274      1.7                  35,784   0.78    0.69--0.87            2      340      2.3                 40,022   0.86    0.77--0.95     4      290     2.9    28,419   1.04    0.92--1.16     5
      Ocular (H00-H59)            166      1.0                  35,784   0.47    0.40--0.54            5      139      1.0                 40,022   0.35    0.29--0.41     5      164     1.7    28,419   0.59    0.50--0.68     11
      Aural (H60-H95)             171      1.1                  35,784   0.49    0.41--0.56            4      241      1.7                 40,022   0.61    0.53--0.69     5      174     1.8    28,419   0.62    0.53--0.72     5
      Cardiovascular (I00-I99)    112      0.7                  35,784   0.32    0.26--0.38            16.5   302      2.1                 40,022   0.77    0.68--0.85     17     233     2.4    28,419   0.83    0.73--0.94     17
      Respiratory (J00-J99)       3,360    20.9                 35,784   9.57    9.25--9.89            3      3,078    21.1                40,022   7.81    7.53--8.09     4      2,014   20.4   28,419   7.21    6.90--7.53     5
      Digestive (K00-K95)         837      5.2                  35,784   2.38    2.22--2.55            3      736      5.1                 40,022   1.87    1.73--2.00     4      556     5.6    28,419   1.99    1.83--2.16     5
      Skin (L00-L99)              145      0.9                  35,784   0.41    0.35--0.48            7      146      1.0                 40,022   0.37    0.31--0.43     11     106     1.1    28,419   0.38    0.31--0.45     9
      Musculoskeletal (M00-M99)   3,075    19.1                 35,784   8.75    8.45--9.07            15     2,631    18.1                40,022   6.68    6.42--6.93     11     2,147   21.8   28,419   7.69    7.36--8.01     13
      Genitourinary (N00-N99)     692      4.3                  35,784   1.97    1.82--2.12            6      772      5.3                 40,022   1.96    1.82--2.10     6      373     3.8    28,419   1.34    1.20--1.47     8
      Obstetric (O00-O9A)         1,120    7.0                  35,784   3.19    3.00--3.28            20     623      4.3                 40,022   1.58    1.46--1.71     17     12      0.1    28,419   0.04    0.02--0.07     23
      Congenital (Q00-Q99)        16       0.1                  35,784   0.05    0.02--0.07            15     19       0.1                 40,022   0.05    0.02--0.07     33.5   11      0.1    28,419   0.04    0.02--0.06     52
      Other (R00-R99)             1,588    9.9                  35,784   4.52    4.30--4.74            3      1,290    8.9                 40,022   3.27    3.10--3.45     4      786     8.0    28,419   2.81    2.62--3.01     5
      Accidents (S00-T88)         820      5.1                  35,784   2.34    2.18--2.50            14     801      5.5                 40,022   2.03    1.89--2.17     15     705     7.2    28,419   2.52    2.34--2.71     19
      External causes (V00-Y99)   142      0.9                  35,784   0.40    0.34--0.47            12     167      1.2                 40,022   0.42    0.36--0.49     14     142     1.4    28,419   0.51    0.42--0.59     25
      Health services (Z00-Z99)   47       0.3                  35,784   0.13    0.10--0.17            14     47       0.3                 40,022   0.12    0.09--0.15     14     29      0.3    28,419   0.10    0.07--0.14     23
  **Contract**                                                                                                                                                                                                                   
      Permanent                   11,321   73.9                 26,130   44.19   43.37--45.00          5      11,080   80.3                32,458   34.67   34.03--35.32   6      7,849   86.1   24,243   32.96   32.23--33.69   7
      Temporary                   3,994    26.1                 8,046    50.64   49.08--52.22          4      2,726    19.7                6,376    43.53   41.90--45.17   5      1,272   13.9   3,565    36.32   34.33--38.32   7
  **Occupational category**                                                                                                                                                                                                      
      Skilled non-manual          3,277    21.4                 8,284    40.25   38.88--41.63          5      3,131    22.7                9,328    34.07   32.88--35.27   5      1,712   18.8   5,752    30.19   28.76--31.62   6
      Unskilled non-manual        8,730    57.0                 17,131   52.07   50.97--53.16          4      6,991    50.6                18,646   38.11   37.22--39.01   5      4,371   47.9   12,087   36.85   35.76--37.94   7
      Skilled manual              2,088    13.6                 4,770    44.76   42.84--46.68          6      2,107    15.3                5,361    40.02   38.31--41.72   6      1,546   16.9   4,124    38.29   36.38--40.20   8
      Unskilled manual            1,220    8.0                  2,563    48.69   45.96--51.42          5      1,577    11.4                3,800    42.34   40.25--44.43   7      1,492   16.4   4,126    37.00   35.12--38.88   9
  **Country of Origin**                                                                                                                                                                                                          
      Spain and EU-28             13,354   87.2                 28,935   47.10   46.30--47.90          5      12,144   88.0                33,846   36.46   35.81--37.11   5      8,176   89.6   25,091   28.83   28.21--29.46   7
      Other                       1,719    11.2                 6,074    28.68   27.33--30.04          6      1,498    10.9                5,606    27.06   25.69--28.43   7      832     9.1    3,017    27.98   26.08--29.88   7
  **Overall**                     15,315   100                  35,784   43.62   42.92--44.31          5      13,806   100                 40,022   35.03   34.45--35.62   5      9,121   100    28,419   32.65   32.01--33.35   7

IR: incidence rate, 95% CI: 95% confidence interval, MD: median duration of SA in days.

\*per 100 person-years.

In regards to diagnostic groups, as shown in [Table 2](#pone.0237794.t002){ref-type="table"}, incidence rates decreased significantly between each of the three age groups, from early-reproductive to late-reproductive for infectious, obstetric, and other poorly specified diseases, and increased for neoplastic diagnoses. There were also significant differences in the incidence rates between each of the age groups for musculoskeletal diagnoses, though the trend was not linear with age. The incidence rate of the musculoskeletal group was lowest in middle-reproductive age, and highest in early-reproductive age women.

Exploring in greater detail specific diseases, gastroenteritis and colitis, low back pain, hemorrhaging during early pregnancy, and vomiting during pregnancy all demonstrated a significant decline in IR between each age group from early-reproductive women to the late-reproductive group ([Table 3](#pone.0237794.t003){ref-type="table"}). The early-reproductive age group also had a significantly higher incidence rate of neck pain (IR = 0.73; 95% CI: 0.64--0.82), nausea and vomiting (IR = 0.56; 95% CI: 0.48--0.63), and abdominal and pelvic pain (IR = 0.56; 95% CI: 0.48--0.63) than the two older age groups.

10.1371/journal.pone.0237794.t003

###### Incidence rates of sickness absence in female workers by age group, according to disease, Catalonia 2012--2014.
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                                                Early-Reproductive   Middle-Reproductive   Late-Reproductive                                                                             
  --------------------------------------------- -------------------- --------------------- ------------------- -------------- ------- ------ ------ -------------- ------- ------ ------ --------------
  Infectious (A00-B99)                          2,195                13.6                  6.25                5.99--6.51     1,611   11.1   4.09   3.89--4.29     838     8.5    3.00   2.80--3.20
      Viral Intestinal Infection (A08-A08.8)    151                  6.9                   0.43                0.36--0.50     126     7.8    0.32   0.26--0.38     56      6.7    0.20   0.15--0.25
      Gastroenteritis & Colitis (A09)           851                  38.7                  2.42                2.26--2.59     634     39.4   2.16   1.48--1.73     298     35.6   1.07   0.95--1.19
      Unlocalized Viral Infection (B34-B34.9)   261                  11.9                  0.74                0.65--0.83     252     15.6   0.64   0.56--0.72     149     17.8   0.53   0.45--0.62
  Neoplasms (C00-D49)                           170                  1.1                   0.48                0.41--0.55     371     2.6    0.94   0.85--1.04     339     3.4    1.21   1.08--1.34
      Malignant Breast Cancer (C50-C50.929)     8                    4.7                   0.02                0.01--0.04     25      6.7    0.06   0.03--0.09     39      11.5   0.14   0.09--0.18
      Lipoma (D17-D17.9)                        3                    1.8                   0.01                \<0.01--0.02   7       1.9    0.02   \<0.01--0.03   15      4.42   0.05   0.03--0.08
      Uterine Fibroid (D25-D25.9)               28                   16.5                  0.08                0.05--0.11     71      19.1   0.18   0.14--0.22     37      10.9   0.13   0.09--0.18
      Benign Ovarian Cancer (D27-D27.9)         11                   6.47                  0.03                0.01--0.05     19      5.12   0.05   0.02--0.07     7       2.1    0.03   0.01--0.04
  Musculoskeletal (M00-M99)                     3,075                19.1                  8.75                8.45--9.07     2,631   18.1   6.68   6.42--6.93     2,147   21.8   7.69   7.36--8.01
      Neck Pain (M54.2)                         258                  8.4                   0.73                0.65--0.82     201     7.6    0.51   0.44--0.58     158     7.4    0.57   0.48--0.65
      Low Back Pain (M54.3-M54.5)               1,027                33.4                  2.92                2.75--3.10     740     28.1   1.88   1.74--2.01     409     19.0   1.46   1.32--1.61
  Obstetric (O00-O9A)                           1,120                7.0                   3.19                3.00--3.28     623     4.3    1.58   1.46--1.71     12      0.1    0.04   0.02--0.07
      Retained Products of Conception (O02.0)   46                   4.1                   0.13                0.09--0.17     34      5.5    0.09   0.06--0.12     0       0      0      
      Spontaneous Abortion (O03-O03.9)          45                   4.0                   0.13                0.09--0.17     67      10.8   0.17   0.13--0.21     0       0      0      
      Early Pregnancy Hemorrhage (O20-O20.9)    94                   8.4                   0.27                0.21--0.32     58      9.3    0.15   0.11--0.19     2       16.7   0.01   \<0.01--0.02
      Vomiting During Pregnancy (O21-O21.9)     88                   7.9                   0.25                0.20--0.30     28      4.5    0.07   0.05--0.11     0       0      0      
      Antepartum Hemorrhage (O46-O46.9)         43                   3.8                   0.12                0.09--0.16     31      5.0    0.08   0.04--0.10     0       0      0      
  Other (R00-R99)                               1,588                9.9                   4.52                4.30--4.74     1,290   8.9    3.27   3.10--3.45     786     8.0    2.81   2.62--3.01
      Abdominal & Pelvic Pain (R10-R10.9)       195                  12.3                  0.56                0.48--0.63     139     10.8   0.35   0.29--0.41     68      8.7    0.24   0.19--0.30
      Nausea & Vomiting (R11-R11.2)             195                  12.3                  0.56                0.48--0.63     107     8.3    0.27   0.22--0.32     60      7.6    0.21   0.16--0.27
      Dizziness (R42)                           109                  6.9                   0.31                0.25--0.37     118     9.1    0.30   0.25--0.35     74      9.4    0.26   0.20--0.33
      Unspecified Fever (R50.9)                 107                  6.7                   0.30                0.25--0.36     77      6.0    0.20   0.15--0.24     55      7.0    0.20   0.14--0.25
      Headache (R51)                            50                   3.1                   0.14                0.10--0.18     56      4.3    0.14   0.10--0.18     26      3.3    0.09   0.06--0.13
      Fatigue (R53-R53.83)                      97                   6.1                   0.28                0.22--0.33     57      4.4    0.14   0.11--0.18     59      7.5    0.21   0.15--0.25

IR: incidence rate, 95% CI: 95% confidence interval.

\* per 100 person-years.

In [Table 4](#pone.0237794.t004){ref-type="table"}, the crude model for overall SA shows that the IRR for the early-reproductive age group (IRR = 1.09; 95% CI: 1.06--1.12) is modestly, yet significantly greater than the late-reproductive age group (IRR = 1 \[reference\]); adjusting for contract, occupational category, and country of origin does not change this pattern. However, when diagnostic group is also taken into account in this model for all SA episodes, this association almost entirely disappeared (Model 2). In regards to the specific diseases in the adjusted model, the IRR in the early-reproductive age group was significantly higher than that of late-reproductive women for viral intestinal infection (IRR = 2.24; 95% CI: 1.33--3.78), gastroenteritis and colitis (IRR = 2.20; 95% CI: 1.73--2.80), low back pain (IRR = 2.11; 95% CI: 1.77--2.52), hemorrhage in early pregnancy (IRR = 33.20; 95% CI: 4.32--246.4), nausea and vomiting (IRR = 2.32; 95% CI: 1.37--3.94), and abdominal and pelvic pain (IRR = 1.86; 95% CI: 1.16--2.98).

10.1371/journal.pone.0237794.t004

###### Estimated incidence risk ratio (IRR) for overall SA and specific diseases among reproductive and late-reproductive age groups in female workers, Catalonia 2012--2014.

![](pone.0237794.t004){#pone.0237794.t004g}

                                                                                                        Model 1   Model 2               
  ----------------------------------------------------------------------------------------------------- --------- ------------- ------- -------------
  **Overall SA[\*](#t004fn002){ref-type="table-fn"}[§](#t004fn004){ref-type="table-fn"}**                                               
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               0.99      0.97--1.02    1.00    0.97--1.03
      Early-Reproductive                                                                                1.09      1.06--1.12    1.04    1.01--1.06
  **Specific SA Diseases[\*\*](#t004fn003){ref-type="table-fn"}[‡](#t004fn005){ref-type="table-fn"}**                                   
  INFECTIOUS                                                                                                                            
  Viral Intestinal Infection                                                                                                            
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               2.17      1.29--3.66    2.02    1.19--3.43
      Early-Reproductive                                                                                2.51      1.50--4.20    2.24    1.33--3.78
  Gastroenteritis & Colitis                                                                                                             
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               1.92      1.51--2.44    1.92    1.50--2.44
      Early-Reproductive                                                                                2.28      1.80--2.89    2.20    1.73--2.80
  Unlocalized Viral Infection                                                                                                           
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               1.02      0.73--1.41    1.01    0.73--1.41
      Early-Reproductive                                                                                0.99      0.72--1.38    0.97    0.69--1.35
  NEOPLASMS                                                                                                                             
  Malignant Breast Cancer                                                                                                               
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               0.39      0.15--1.07    0.52    0.19--1.44
      Early-Reproductive                                                                                0.14      0.04--0.46    0.19    0.06--0.64
  Lipoma                                                                                                                                
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               0.33      0.11--0.96    0.32    0.11--0.95
      Early-Reproductive                                                                                0.07      0.01--0.51    0.06    0.01--0.51
  Uterine Fibroid                                                                                                                       
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               1.31      0.72--2.38    1.29    0.70--2.37
      Early-Reproductive                                                                                0.61      0.31--1.19    0.61    0.40--1.22
  Benign Ovarian Cancer                                                                                                                 
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               2.66      0.86--8.25    2.72    0.87--8.50
      Early-Reproductive                                                                                0.82      0.21--3.16    0.85    0.22--3.31
  MUSCULOSKELETAL                                                                                                                       
  Neck Pain                                                                                                                             
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               0.79      0.55--1.14    0.86    0.59--1.24
      Early-Reproductive                                                                                1.12      0.80--1.58    1.17    0.82--1.66
  Low Back Pain                                                                                                                         
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               1.46      1.22--1.75    1.47    1.22--1.77
      Early-Reproductive                                                                                2.10      1.76--2.49    2.11    1.77--2.52
  OBSTETRIC                                                                                                                             
  Early Pregnancy Hemorrhage                                                                                                            
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               18.82     2.51--141.4   18.33   2.43--138.2
      Early-Reproductive                                                                                32.58     4.40--241.0   33.20   4.32--246.4
  OTHER                                                                                                                                 
  Abdominal & Pelvic Pain                                                                                                               
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               1.52      0.95--2.42    1.61    1.00--2.59
      Early-Reproductive                                                                                1.78      1.13--2.81    1.86    1.16--2.98
  Nausea & Vomiting                                                                                                                     
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               1.35      0.77--2.34    1.42    0.81--2.47
      Early-Reproductive                                                                                2.23      1.32--3.77    2.32    1.37--3.94
  Dizziness                                                                                                                             
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               1.08      0.67--1.72    1.14    0.71--1.83
      Early-Reproductive                                                                                0.81      0.50--1.33    0.88    0.53--1.45
  Unspecified Fever                                                                                                                     
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               0.76      0.45--1.28    0.71    0.42--1.21
      Early-Reproductive                                                                                0.91      0.55--1.50    0.90    0.54--1.49
  Headache                                                                                                                              
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               2.23      0.98--5.06    2.23    0.98--5.08
      Early-Reproductive                                                                                1.40      0.59--3.29    1.27    0.54--3.03
  Fatigue                                                                                                                               
      Late-Reproductive                                                                                 1                       1       
      Middle-Reproductive                                                                               0.66      0.35--1.23    0.65    0.35--1.22
      Early-Reproductive                                                                                1.47      0.86--2.53    1.40    0.81--2.43

cIRR = crude incidence risk ratio; aIRR = adjusted incidence risk ratio; 95% CI = 95% confidence interval.

\* Adjusted for diagnostic group, occupational category, type of contract, and country of origin

\*\* Adjusted for occupational category, type of contract, and country of origin

§ Poisson regression

‡ Negative binomial regression.

Discussion {#sec012}
==========

The results of this study show that women in early-reproductive age have an increased risk of initiating a SA spell compared to the late-reproductive age group, this contrasts with previous literature that demonstrates an increased risk of SA with older age \[[@pone.0237794.ref009],[@pone.0237794.ref016]\]. A possible explanation could be found in the healthy worker effect, which describes how healthy workers remain in the workforce longer than those who are not, due to early termination or retirement. In this sense, it is possible that the late-reproductive group has a relatively higher proportion of healthier individuals than the early- or middle-reproductive groups, especially as the healthy worker effect is stronger in women \[[@pone.0237794.ref017]\], potentially leading to the lower incidence of SA observed in late-reproductive female workers.

In addition, the moderately increased risk of SA in early-reproductive aged women appears to be almost entirely explained by diagnostic groups and not occupational characteristics. This suggests that for SA, the type of diseases for which a woman needs to take an absence is more influential on the likelihood a woman starts a SA spell than occupational category, type of contract, or country of origin.

In regards to the higher risk of gastroenteritis, colitis, and other viral intestinal infections in early-reproductive women, few studies have described the age-dependent epidemiology of these diseases in adults. An English study found a slight decreasing incidence of *Campylobacter* infections from women aged 25--29 through 40--44 \[[@pone.0237794.ref023]\], though the study did not offer explanations for this trend. Of note, abdominal and pelvic pain, and nausea and vomiting are both symptoms of intestinal infections. With all of these diagnoses presenting higher risks in early-reproductive women, it is difficult to determine to what degree there might have been confluence of symptom and cause of the disease in assigning diagnoses.

For low back pain, abdominal and pelvic pain, and nausea and vomiting, early-reproductive age also significantly increases the risk of starting SA. Higher incidences of these common health conditions during pregnancy should be expected in early-reproductive women, who have the highest birthrate. Obstetric diagnoses, including early pregnancy hemorrhage, are the most dramatic example of the pattern of higher incidence rates of SA in early-reproductive women.

The trend of decreasing incidence of SA due to obstetric diagnoses as age increases is in accordance with the trend of a decreasing birthrate with older age in this population. Interestingly, there are other diagnostic groups in which the incidence trend significantly decreases from the highest rates in early-reproductive to lowest in late-reproductive women. Some of those diagnosis groups contain pathologies, which could be linked not only to factors related to age itself, but to the different birthrates along the life course, such as musculoskeletal, genitourinary, and other poorly-defined diseases \[[@pone.0237794.ref024]\]. Low back pain, nausea and vomiting, and pelvic girdle pain are some of the most common diseases during pregnancy, and contribute to much of the SA throughout this physiological state \[[@pone.0237794.ref024]--[@pone.0237794.ref027]\]. The significantly higher IR and IRR observed for early-reproductive and, to a lesser extent (IRR not significantly higher), middle-reproductive groups compared to the late-reproductive women in this cohort, suggests that reproductive age is an important predictor for SA episodes due to these symptoms, which are known to be frequent in pregnancy. Additionally, the high incidence of SA in early-reproductive age due to obstetric diagnoses and low back pain coupled with the increased risk observed in early-reproductive age women, potentially due to pregnancy, may partially explain the higher overall IRR in early-reproductive women compared to late-reproductive women.

Furthermore, Arcas *et al*. found that SA due to low back pain had a peak in duration in women aged 26--35, but not in men of the same age \[[@pone.0237794.ref028]\]. This reinforces the idea that SA episodes for low back pain in early- and middle-reproductive age women in this cohort could be related to higher birthrates, since this increase was only described in women and SA spells in pregnancy have longer durations than the average SA length \[[@pone.0237794.ref004],[@pone.0237794.ref029]\]. In this study, young-reproductive women exhibited the longest duration of SA due to musculoskeletal diagnoses of the three age groups. However, no conclusions about pregnancy and the increased IRR for low back pain in younger women can be made from this study, as it could be attributable to other factors such as child care and other unpaid domestic work demands \[[@pone.0237794.ref022],[@pone.0237794.ref024]\].

These results suggest that higher birthrates could explain the increased risk of initiating SA observed in early-reproductive-aged women. While this may sound intuitive, it may be indicative that workplace accommodations or social benefits for pregnant women are insufficient. In a cohort study with hospital employees in Catalonia, Villar and colleagues found, that pregnant women most frequently left employment before birth through an SA spell, rather than an available pregnancy occupational risk benefit or maternity leave \[[@pone.0237794.ref030]\]. Studies have demonstrated that job adjustment can decrease SA incidence \[[@pone.0237794.ref031]\], and general absences \[[@pone.0237794.ref032]\] in pregnant women who reported needing adjustment, which could help improve future employment opportunities for women after childbirth \[[@pone.0237794.ref033]\]. Future studies are needed to confirm the relationship between pregnancy and the increased risk of SA in younger working women, and to identify why women opt for SA over other benefits designed to protect working pregnant women. Additionally, subsequent research should investigate if the longer duration of SA episodes in late-reproductive women observed in this study is a contributing factor to the decrease in SA incidence with decreasing birthrates. However, this current study does not initially seem to support that relationship, as the trend of decreasing incidence of SA with lower birthrates is not mirrored by an increasing trend in SA duration. Rather an increase in SA duration is only observed in the late-reproductive group.

The main limitation of this study is the absence of data indicating how many women were pregnant, and number of pregnancies prior to and during the study period. However, we were able to approximate the effects of pregnancy by stratifying by age based on birthrates. While the age grouping may potentially lead to classification bias, the decreasing incidence rates of obstetric-related SA in older age groups suggests that the groups accurately capture birthrates, and further supports the interpretation of our findings. Our data did not include information on family structure, which is closely related to the number of children a woman decides to have, and the age in which she has them \[[@pone.0237794.ref034]\], and could affect how they cope with the conflict between domestic tasks, work balance, and career development. Furthermore, data on full-time or part-time employment was not available for this study. Those who are employed full-time may be expected to incur more SA, though type of contract provides similar information about the occupational context, and was able to be analyzed in the study. Yet, the available data on socioeconomic and occupational characteristics of the women included in the analysis allow us to account for the possible influence of the occupational context.

An important strength of this study is that it is founded in the linkage of two administrative registries, allowing for a large sample size and the calculation of incidence rates based on exact person-years. This represents one of the few studies examining SA trends by medical diagnosis in women in Southern Europe \[[@pone.0237794.ref024],[@pone.0237794.ref025]\], which is characterized by a relatively weak welfare state in comparison to other Northern European countries, where most research on SA in pregnancy has been performed \[[@pone.0237794.ref035]\]. Identifying the diagnoses that contribute most to the overall effect of increased risk of SA in young-reproductive women can help inform allocation of healthcare resources, mitigation strategies in the workplace, and policy aimed to guard workers' health. Similarly, this is one of the few studies that attempts to explore the incidence of SA in pregnancy-related diseases.

In summary, these results suggest that the differences in SA between early- and late-reproductive-aged women can largely be explained by the higher incidences of infectious, obstetric, and musculoskeletal diseases in younger working women with higher birthrates. Moreover, the higher risk of SA for these diseases in early-reproductive women suggests that greater efforts should be made in the workplace to accommodate younger women with such symptoms, especially for pregnant women for whom these are common diseases, and sources of SA. Building in more flexibility to current maternity leave policies would give pregnant women more options in managing their health during pregnancy, and could reduce dependence on SA.

Supporting information {#sec013}
======================

###### SA Catalan birthrates.

(XLSX)

###### 

Click here for additional data file.

We thank the Spanish National Social Security Institute and the Catalonian Institute for Medical Evaluations for transferring data from the Continuous Working Life Sample and sickness absence registers, respectively. We would like to thank Julio C. Hernando-Rodríguez for his help with the data set.

10.1371/journal.pone.0237794.r001

Decision Letter 0

Magnus

Maria Christine

Academic Editor

© 2020 Maria Christine Magnus

2020

Maria Christine Magnus

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

17 Apr 2020

PONE-D-20-06019

Do birthrates contribute to sickness absence differences in women? A cohort study in Catalonia, Spain, 2012-2014

PLOS ONE

Dear Mr. March,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 01 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Maria Christine Magnus, MPH

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements:

1.    Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3\. One of the noted authors is a group or consortium \[Research Group on Statistics, Econometrics and Health (GRECS)\]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The aim of the study was to investigate differences in sickness absence rates between different age groups with different fertility rates.

However there are some important methodological problems and the study do not add much knowledge to the area.

Their dependent variabel is numbers of sickness absence spells given as IR (numbers of SA spells/100 employment years).

The independent variable is three age groups with different fertility rates.

I have two main concerns regarding the methodology:

1\)

How do they count employment years. No information is given regarding censoring and do they take into account other reasons for absence ie maternity leave. What about the duration of SA spells? Could it be, that older women have longer spells and thus fewer numbers of spells?

Risktime in the different is not stated anywhere - not in the tables nor in the text.

2\)

They have no knowledge of pregnancies among the women, thus the independent variable is only a proxy

The methods section is very short and not sufficient informative. There is no flow chart explaining how the final population was reached and it is sparsely described in the text. At what dates do the study start and end?

Regarding results:

There is no table 1 describing the different age groups with regard to contract types, occupations, country of origin, mean age, mean duration of SA spells, risk time, numbers of women etc.

Regarding conclusion

They conclude that results suggest that differences in sickness absence between early- and late reproductive groups can largely be explained by higher incidence of infectious, obstetric and musculosceletal disorders in younger women with (they write lower birthrates, I think they mean higher birth rates) higher birthrates.

First the overall IRR in the fully adjusted model is 1.04, which in this study with many

uncertainties, is not compelling.

Second the found difference in IR of diseases related to pregnancy is not surprising, but I am not convinced that it can explain the difference, if any, in overall SA.

Reviewer \#2: General comments:

This study is focusing on a topic that is becoming increasingly important as female employment rates are growing in many countries. The study does provide some interesting findings.

However, I have some major concerns:

• A major limitation is that the analyses do not include information about working hours, or part time vs full time employment. Since the extent of part time employment is widespread among women, this might be an important confounder, which has received no attention at all.

• It is not clear how the study brings new knowledge to the research field.

• The study is generally marked by a lack of precision. For example, it is unclear whether all sickness absence spells are included, or whether spells are recorded after a certain number of days.

• The study lacks important information about the quality of the research data.

Specific comments:

Abstract:

26

Please clarify this aim. What is meant by \"distribution of sickness absence trends\"? Sickness absence differentials between age groups? Trends in sickness absence across age groups? It is not clear what the term "distribution" contributes with in this aim.

30

What is the percentage? (How many percent do the 47879 female employees constitute of the total population of female employees in the current age groups during this period of time?)

32

It seems a bit odd that the study excludes women younger than 25, when women as old as 54 are included. Please clarify. Also, the age groups are quite large, is it possible to make them smaller? For example 25-29 in one group, and 30-35 in the next?

34

Do these registries not include information about working hours, or the proportion of part time /full time employment among these women? This is particularly important when analyzing the impact of fertility on sickness absence among women, because longer working hours probably apply more often to younger women who do not have children.

Introduction:

56

What kind of legislation? EU-legislation? Legislation in Catalonia? It is not clear if legislation actually has been changed, or if there simply is a growing recognition of the need for doing so. How is this study related to the (need for) changing legislation?

70

Is this the kind of legislation that were mentioned in the first paragraph? In that case, the legislation should not be introduced until it is addressed more fully, that is, in the third paragraph.

77

Is confusing that the term \"SA\" refers to both \"sickness absence\" (being away from work) and \"sickness absence benefit\" (social insurance benefit). Please use different terms to distinguish between these.

84-85

What does it mean that spells are \"reported\"? Is that the same as being recorded in the registry that your study applies? What separates spells that are recognized by a National Health Service physician from spells that are not? Is the physician involved even the first few days when the worker gets no compensation, after 3 days when the employer covers the employment, or from day 17 when the National Social Security covers the pay, or at some other time? If spells are not recorded in the registry from the first sick day, but rather after a particular length of duration, please consider if this implies that the dependent variable in this study is truncated, and if so, if other regression models are more suitable than Poisson and negative binomial regression.

99

In the Abstract there seem to be one aim specified, but in line 99 there seem to be several aims. Please be consistent.

Please provide more information about any maternity leave scheme, the overall fertility rate, mean age for first-time pregnant women, and the level of employment among pregnant women in Catalonia.

Methods:

104

Please give more details about the quality of the data. What is the purpose of these registries? What is the level of reliability? Are the registries characterized by any weaknesses?

119

Does the dependent variable not account for the wide extent of part time employment among Spanish women? Full time employed women will probably have many more SA spells than part time employed women. This should be accounted for in the analyses. If it is not possible to account for this, the implications for the findings should be thoroughly discussed.

Also, it is unclear if it includes all possible sickness absence spells, or only spells recognized by the National Health Service physicians.

144

This seems a bit odd because \"affiliate-years\" is not a widely accepted term. Please use more common language.

152

Please explain why these types of regression (Poisson and the negative bionomial) were applied.

158

Please provide some more information about the ethics approval. Is this paper part of a larger study that was approved by the Committee? If so, what kind of study is that?

Results:

163-165

Please consider the possibility that age differentials in SA partly result from age specific patterns in part-time employment. Considering that female employment has increased in Spain recently, one might expect that younger women are more likely to longer working hours than older women, (particularly if the latter group more often have children). If so, one would expect younger women to have higher rates of sickness absence, simply because they work longer hours. This implies that working hours is an important possible confounder that should be included in the analyses. If that is not possible, the possible implications of this limitation should be properly discussed.

It is confusing that the results are characterized as "significant" in the text, as statistical significance is not easily detectable from the tables. For example, it is possible that overlapping confidence intervals yield significantly different point estimates (IRs). I would recommend an extra column with a p-value for the trend (early-middle-late).

Discussion:

327

If the study's main contribution to the research field is that it provides empirical analyses from Southern Europe, this should be included and elaborated on in the introduction.

335

According to the above text, younger working women have higher, not lower birthrates (which is stated here).

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237794.r002

Author response to Decision Letter 0

14 Jun 2020

A document containing response to reviewers has been attached to this submission.

###### 

Submitted filename: PLOSONE Reviewer Responses_final.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0237794.r003

Decision Letter 1

Magnus

Maria Christine

Academic Editor

© 2020 Maria Christine Magnus

2020

Maria Christine Magnus

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

9 Jul 2020

PONE-D-20-06019R1

Do birthrates contribute to sickness absence differences in women? A cohort study in Catalonia, Spain, 2012-2014

PLOS ONE

Dear Dr. March,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
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